CDKN2A Mutation

CI-VAR-00002705Explore in graph →CIViC 2704

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 5 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Burkitt Lymphoma1
CDKN2A Mutation	(oncogenic)	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11815 Mutations have been described in several studies including the one cited. PMID 30617194 · Grande et al., 2019 · Open in CIViC	civic
Cholangiocarcinoma2
CDKN2A Mutation	Palbociclib	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID7300 In a phase 2 trial, patients with gallbladder cancer or bile duct cancer with CDKN2A loss or mutation were received palbociclib. Among 10 patients, no overall response or stable disease at 16 weeks we… (full text at CIViC) Open in CIViC	civic
FGFR2 Mutation AND CDH1 MUTATION AND CDKN2A Mutation AND CDKN2B Mutation

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Non-Small Cell Carcinoma1
RB1 Wildtype AND ( CDKN2A Loss OR CDKN2A Mutation )	Palbociclib	Predictive	B	Supports Sensitivity Response	3	accepted	EID11665 A phase II clinical study was conducted with 29 patients with Non-Small-Cell Lung Cancer harboring CDKN2A alterations and wild-type Rb. The study reported one patient with a partial response, and six … (full text at CIViC) PMID 35050752 · Ahn et al., 2020 · Open in CIViC	civic

Malignant Biliary Tract Neoplasm1
CDKN2A Loss OR CDKN2A Mutation	Palbociclib	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11654 A phase II clinical study conducted in 10 patients with biliary cancer with CDKN2A loss or mutation, that were treated with palbociclib. No clinical activity demonstrated in patients with CDKN2A mutat… (full text at CIViC) PMID 35100714 · Al Baghdadi et al., 2019 · Open in CIViC	civic

Malignant Pancreatic Neoplasm2
CDKN2A Loss OR CDKN2A Mutation	Palbociclib	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11653 A phase II clinical study conducted with 12 patients with pancreatic cancer with CDKN2A loss or mutation treated with palbociclib. No clinical activity demonstrated in patients with CDKN2A mutated/del… (full text at CIViC) PMID 35100714 · Al Baghdadi et al., 2019 · Open in CIViC	civic
CDKN2A Mutation	Palbociclib	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID7299 In a phase 2 trial, patients with pancreatic cancer with CDKN2A loss or mutation were received palbociclib. Among 12 patients no overall response or stable disease at 16 weeks were observed. Open in CIViC	civic